Clinicopathological Analysis of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review of 9 Cases

Table 1

Patient characteristics (N = 9).

		Number/mean/median	%/SD/Min–Max
Age (mean, SD)		58, 5	±16, 1
Gravida (median, Min–Max)		5	2–8
Parity (median, Min–Max)		4	1–7
BMI (mean, SD)		24, 4	±2, 3
Ca 125 (median, Min–Max)		24, 5	8, 1–264, 2
Cigarette (mean, SD)	Pack/year	12, 1	±9, 5
Mode of delivery	NVD	7	22, 2
	C/S	2	77, 8
Education status	Illiterate	5	55, 6
	Primary school ≤	4	44, 4
Smear result	Absent	5	55, 6
	Normal	2	22, 2
	HSIL	2	22, 2
First complaint	Postcoital bleeding	3	33, 3
	Pelvic pain	2	22, 2
	Postmenopausal bleeding	3	33, 3
	Vaginal discharge	1	11, 1
Histological type	Neuroendocrine	9	1, 98
	Others	444	98, 01
Stage	Early	3	33, 1
	Locally advance	5	55, 5
	Metastatic	1	11, 1
Stage subgroup (FIGO)	1b2	3	33, 3
	2b	4	44, 4
	3c2r	1	11, 1
	4b	1	11, 1
Treatment modality	Primary CRT	3	33, 1
	Surgery + adj. CRT	6	66, 6
L/S	Done	2	22, 2
	Not done	7	77, 8
LVSI status	Negative	2	22, 2
	Positive	7	77, 8
Lymph status	Negative	6	66, 7
	Positive	3	33, 3
Recurrence	Present	3	33, 3
	Absent	6	66, 7
Death	Present	5	55, 6
	Absent	4	44, 4
Follow-up (month)		26 (6–208)

FIGO, International Federation of Gynecology and Obstetrics; BMI, body mass index; NVD, normal vaginal delivery; CS, caesarean section; CRT, chemoradiotherapy treatment; and LVSI, lymphovascular space involvement.